117 KENDRICK STREET, NEEDHAM, MA
Verastem Oncology Reports Positive Preliminary Results from VS-7375 Trial in KRAS G12D Mutant Solid Tumors
Updated Data on GFH375 for KRAS G12D Mutant Pancreatic Cancer by Verastem Oncology and GenFleet
Delivering Novel Therapies for RAS/MAPK Pathway Driven Cancers Presentation | September 2025
Verastem Oncology's Late-Breaking Study on GFH375 for Lung Cancer at IASLC 2025
R&D Investor Event ASCO 2025 June 2, 2025
Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
Verastem Oncology's Positive Results for Avutometinib & Defactinib in Metastatic Pancreatic Cancer
Reg. FD, Other Events
Q2
Q1
Q3
FY 2023
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities